Literature DB >> 19667994

Therapy for pulmonary arterial hypertension associated with systemic sclerosis.

Stephen C Mathai1, Paul M Hassoun.   

Abstract

PURPOSE OF REVIEW: Systemic sclerosis is commonly complicated by pulmonary arterial hypertension (PAH-SSc) and is a leading cause of death in this population. We will review existing challenges and recent advances in the treatment of this disease. RECENT
FINDINGS: Traditionally employed outcome measures in pulmonary arterial hypertension research may not be applicable in PAH-SSc. Importantly, new therapies that target abnormal cellular proliferation in the pulmonary vasculature are currently under investigation and may be particularly relevant to PAH-SSc.
SUMMARY: Pulmonary arterial hypertension complicating systemic sclerosis occurs commonly and portends a poor prognosis. However, recent advances in our understanding of the disease in the context of systemic sclerosis may lead to novel diagnostic and therapeutic strategies that will ultimately improve quality of life and survival in this population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667994      PMCID: PMC2858398          DOI: 10.1097/BOR.0b013e3283307dc8

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  64 in total

Review 1.  Endothelial dysfunction in pulmonary hypertension.

Authors:  Rohit Budhiraja; Rubin M Tuder; Paul M Hassoun
Journal:  Circulation       Date:  2004-01-20       Impact factor: 29.690

Review 2.  Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Vallerie V McLaughlin; Kenneth W Presberg; Ramona L Doyle; Steven H Abman; Douglas C McCrory; Terry Fortin; Gregory Ahearn
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

3.  Lessons learned from cancer may help in the treatment of pulmonary hypertension.

Authors:  Serge Adnot
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

4.  Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.

Authors:  Gideon A Paul; J Simon R Gibbs; Alan R Boobis; Allifia Abbas; Martin R Wilkins
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

5.  Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.

Authors:  L J Rubin; J Mendoza; M Hood; M McGoon; R Barst; W B Williams; J H Diehl; J Crow; W Long
Journal:  Ann Intern Med       Date:  1990-04-01       Impact factor: 25.391

6.  Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

Authors:  Olivier Sitbon; Marc Humbert; Xavier Jaïs; Vincent Ioos; Abdul M Hamid; Steeve Provencher; Gilles Garcia; Florence Parent; Philippe Hervé; Gérald Simonneau
Journal:  Circulation       Date:  2005-06-06       Impact factor: 29.690

7.  Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry.

Authors:  G G Pietra; W D Edwards; J M Kay; S Rich; J Kernis; B Schloo; S M Ayres; E H Bergofsky; B H Brundage; K M Detre
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

8.  Sitaxsentan therapy for pulmonary arterial hypertension.

Authors:  Robyn J Barst; David Langleben; Adaani Frost; Evelyn M Horn; Ronald Oudiz; Shelley Shapiro; Vallerie McLaughlin; Nicholas Hill; Victor F Tapson; Ivan M Robbins; Diane Zwicke; Benjamin Duncan; Richard A F Dixon; Lyn R Frumkin
Journal:  Am J Respir Crit Care Med       Date:  2003-11-20       Impact factor: 21.405

Review 9.  A study of the prevalence of systemic sclerosis in northeast England.

Authors:  R J Allcock; I Forrest; P A Corris; P R Crook; I D Griffiths
Journal:  Rheumatology (Oxford)       Date:  2004-02-10       Impact factor: 7.580

10.  Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.

Authors:  Ronald J Oudiz; Robert J Schilz; Robyn J Barst; Nazzareno Galié; Stuart Rich; Lewis J Rubin; Gérald Simonneau
Journal:  Chest       Date:  2004-08       Impact factor: 9.410

View more
  9 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis.

Authors:  Theodoros Dimitroulas; Sophie Mavrogeni; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2012-02-07       Impact factor: 20.543

3.  Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.

Authors:  Edward A Pankey; Matthew Epps; Bobby D Nossaman; Albert L Hyman; Philip J Kadowitz
Journal:  J Clin Rheumatol Musculoskelet Med       Date:  2010-12-01

4.  Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension.

Authors:  Eileen Hsu; Haiwen Shi; Rick M Jordan; James Lyons-Weiler; Joseph M Pilewski; Carol A Feghali-Bostwick
Journal:  Arthritis Rheum       Date:  2011-03

Review 5.  Cardiac manifestations in systemic sclerosis.

Authors:  Sevdalina Lambova
Journal:  World J Cardiol       Date:  2014-09-26

Review 6.  Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions.

Authors:  Silvia Bellando-Randone; Marco Matucci-Cerinic
Journal:  Curr Rheumatol Rep       Date:  2017-09-18       Impact factor: 4.592

7.  Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).

Authors:  Kathleen D Kolstad; Shufeng Li; Virginia Steen; Lorinda Chung
Journal:  Chest       Date:  2018-05-16       Impact factor: 9.410

Review 8.  Treatment of pulmonary arterial hypertension in connective tissue disease.

Authors:  Ekkehard Grünig
Journal:  Drugs       Date:  2012-05-28       Impact factor: 11.431

Review 9.  Advances in the management of pulmonary arterial hypertension.

Authors:  Himanshu Deshwal; Tatiana Weinstein; Roxana Sulica
Journal:  J Investig Med       Date:  2021-10       Impact factor: 2.895

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.